Preliminary results of a phase II study of chemoimmunotherapy (rituximab plus FAB chemotherapy) in children and adolescents with intermediate risk B-cell NHL: A children's oncology group report

被引：0
|
作者：
Goldman, S. [1 ]
Lynch, J. [1 ]
Davenport, V. [1 ]
Perkins, S. [1 ]
Shiramizu, B. [1 ]
Sanger, W. [1 ]
Gross, T. [1 ]
Harrison, L. [1 ]
Bancroft, M. [1 ]
Cairo, M. S. [1 ]
机构：
[1] COG Childrens Oncol Grp, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：109 / 110
页数：2
相关论文
共 50 条
  • [1] Safety, Efficacy and Rituximab Levels Following Chemoimmunotherapy (Rituximab plus FAB Chemotherapy) in Children and Adolescents with Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children's Oncology Group Report
    Cairo, Mitchell S.
    Lynch, James
    Harrison, Lauren
    van de Ven, Carmella
    Gross, Thomas
    Shiramizu, Bruce
    Sanger, Warren
    Perkins, Sherrie L.
    Goldman, Stanton
    BLOOD, 2008, 112 (11) : 310 - 310
  • [2] Safety and pharmacokinetics of rituximab in combination with FAB chemotherapy in children and adolescents with Stage III/IV mature B-NHL and B-cell leukemia ± CNS disease: a Children's Oncology Group Report
    Barth, M. J.
    Goldman, S.
    Zhi, J.
    Smith, L.
    Harrison, L.
    Perkins, S. L.
    Shiramizu, B.
    Gross, T.
    Sanger, W.
    Cairo, M. S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 : 23 - 23
  • [3] OUTCOME AND PHARMACOKINETIC (PK) ANALYSIS OF ADDING RITUXIMAB TO FAB CHEMOTHERAPY IN CHILDREN AND ADOLESCENTS WITH ADVANCED MATURE B-NHL/LEUKEMIA: A CHILDREN'S ONCOLOGY GROUP REPORT
    Goldman, Stan
    Smith, Lynette
    Perkins, Sherrie
    Shiramizu, Bruce
    Gross, Thomas
    Sanger, Warren
    Harrison, Lauren
    Cairo, Mitchell
    PEDIATRIC BLOOD & CANCER, 2011, 57 (05) : 737 - 738
  • [4] The Efficacy of Rasburicase and Rituximab Combined with FAB Chemotherapy in Children and Adolescents with Newly Diagnosed Stage III/IV, BM plus and CNS plus Mature B-NHL: A Children's Oncology Group Report
    Goldman, Stanton
    Galardy, Paul J.
    Smith, Lynette
    Perkins, Sherrie L.
    Shiramizu, Bruce
    Gross, Thomas
    Sanger, Warren G.
    Harrison, Lauren
    Cairo, Mitchell S.
    BLOOD, 2011, 118 (21) : 1161 - 1162
  • [5] Outcome of advanced stage (III/IV) intermediate-risk patients with mature B-NHL using rituximab plus FAB group B4 chemotherapy: a Children's Oncology Group report
    Goldman, S.
    Smith, L.
    Anderson, J. R.
    Perkins, S.
    Harrison, L.
    Shiramizu, B.
    Sanger, W.
    Barth, M.
    Cairo, M. S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 : 24 - 24
  • [6] Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report
    Barth, Matthew J.
    Goldman, Stanton
    Smith, Lynette
    Perkins, Sherrie
    Shiramizu, Bruce
    Gross, Thomas G.
    Harrison, Lauren
    Sanger, Warren
    Geyer, Mark B.
    Giulino-Roth, Lisa
    Cairo, Mitchell S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (05) : 678 - 683
  • [7] RESULTS OF THE ADDITION OF RASBURICASE(RU) AND RITUXMAB(RM) TO THE FAB/LMB96 CHEMOTHERAPY BACKBONE IN CHILDREN plus ADOLESCENTS(C plus A) WITH MATURE B-NHL:A CHILDREN'S ONCOLOGY GROUP REPORT
    Cairo, Mitchell S.
    Lynch, James
    Harrison, Lauren
    Perkins, Sherrie
    Sanger, Warren
    Gross, Thomas
    Shiramizu, Bruce
    Goldman, Stanton
    PEDIATRIC BLOOD & CANCER, 2009, 53 (05) : 858 - 858
  • [8] Preliminary Results of the Addition of Rasburicase to the Reduction Cycle and Rituximab to the Induction and Consolidation Cycles of FAB Group C Chemotherapy in Children and Adolescents with Advanced Stage (Bone Marrow +/-CNS) Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children's Oncology Group Report
    Goldman, Stanton
    Lynch, James
    Harrison, Lauren
    Gross, Thomas
    Shiramizu, Bruce
    Sanger, Warren
    Perkins, Sherrie L.
    Cairo, Mitchell S.
    BLOOD, 2009, 114 (22) : 48 - 48
  • [9] Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C plus A) with stage III/IV (Group B) and BM plus /CNS plus (Group C) mature B-NHL: A Children's Oncology Group report.
    Cairo, M. S.
    Lynch, J. C.
    Harrison, L.
    Perkins, S. L.
    Shiramizu, B.
    Gross, T. G.
    Sanger, W.
    Goldman, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report
    S Goldman
    L Smith
    J R Anderson
    S Perkins
    L Harrison
    M B Geyer
    T G Gross
    H Weinstein
    S Bergeron
    B Shiramizu
    W Sanger
    M Barth
    J Zhi
    M S Cairo
    Leukemia, 2013, 27 : 1174 - 1177
12345